FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>STATEMENT</b>	<b>OF CHANGI</b>	ES IN BEN	EFICIAL (	OWNERS	HIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average	burden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

											<u> </u>								
1. Name and Address of Reporting Person*  NOVAKOVIC PHEBE N				2. Issuer Name <b>and</b> Ticker or Trading Symbol ABBOTT LABORATORIES [ ABT ]								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)						
NO VAIXO VICTILEDE IN												X Directo			10% Ow				
(Last) (First) (Middle) C/O GENERAL DYNAMICS CORPORATION.			)N.	3. Date of Earliest Transaction (Month/Day/Year) 04/26/2019								Officer below)	(give title		Other (s below)	pecify			
		ARK DRIVE, SU		11,															
	III VIL VV 17	max Blav E, 50	J11L 100		4.1	If Ame	ndment. [	Date o	of Original	Filed	(Month/Da	av/Yea	ar)	6. Ir	ndividual or 3	Joint/Group	Filina	(Check Apr	licable
(Street)							,				(	.,	/	Line	e)		J	`	
FALLS CHURC	H V	A	22042													iled by Mor		rting Persor One Repor	
															Persor	ı			
(City)	(S	tate)	(Zip)																
		Tak	le I - Noi	n-Deriv	ativ	e Se	curities	s Acc	quired,	Dis	osed o	of, oı	r Ben	eficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transa Date (Month/L				Execution Date		Date,	e, Transaction Di Code (Instr. 5)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				Beneficia	es ally Following	Form:	Direct Conditions of the Direct Indirect Extr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount		(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			insu. 4)
Common shares without par value			04/26	/201	2019 A 2,241 <sup>(1)</sup> A \$0		26,	26,333		D									
			Table II -								sed of, onverti				Owned				
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date, T	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Security	8. Price of Derivative Security (Instr. 5)		e Constant of the constant of	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirec Beneficial Ownershi (Instr. 4)
				c	ode	v	(A)		Date Exercisab		xpiration ate	Title		or Number of Shares					
Option	<b>\$70.00</b>	0.4/2.0/2010			, ]		40.00		0.4/2.6/2.01	, [	4/25/2020	Con	nmon	10 027		10.00	_ T		

## **Explanation of Responses:**

buy)<sup>(2)</sup>

- 1. These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- 2. Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Jessica H. Paik, by Power of

Attorney for Phebe N.

Novakovic

\*\* Signature of Reporting Person

Date

04/30/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare and sign any and all Securities and Exchange Commission ("SEC") Notices of Proposed Sales of Securities pursuant to Rule 144 under the Securities Act of 1933 on Form 144, all SEC statements on Forms 3, 4 and 5 as required under Section 16(a) of the Securities Exchange Act of 1934, including a Form ID and any other documents necessary to obtain codes and passwords necessary to make electronic filings, and any amendments to such forms, and to file the same with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to file Forms 144, 3, 4, or 5 or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: December 14, 2018

/s/ Phebe N. Novakovic Signature of Reporting Person

Phebe N. Novakovic

Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064